DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Iniparib is an investigational drug.
There have been 20 clinical trials for Iniparib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Sanofi, BiPar Sciences, and SOLTI Breast Cancer Research Group.
Recent Clinical Trials for Iniparib
|Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial||Sanofi||Phase 3|
|A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors||Sanofi||Phase 1|
|Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients||SOLTI Breast Cancer Research Group||Phase 2|